Neonato afecto del síndrome del ácido valproico fetal

Mesegué Medà, Montserrat; Arca Díaz, Gemma; Salvia Roigés, Maria Dolors; Figueras Aloy, Josep.
Pediatr. catalan ; 73(2): 63-65, abr.-jun.2013. tab, ilus
Artículo en Español | IBECS (España) | ID: ibc-114030

Documentos relacionados

  1. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
  2. How much is too much? The implications of recognising alcohol as a teratogen.
  3. Prescription of sodium valproate to women of childbearing potential in Southern District Mental Health Services in New Zealand.
  4. Identification of misclassified pregnancy episodes in women of childbearing potential exposed to drugs with known teratogenic potential in the CPRD GOLD Pregnancy Register.
  5. Congenital anomalies and spontaneous abortion in mice resulting from the use of escitalopram.
  6. A preventable teratology: isotretinoin.
  7. [Conditions are met for a first identification situation of an environmental teratogen].
  8. Re: Antidepressant use and pregnancy: promoting risk minimisation for all teratogens is overdue.
  9. Teratogens and teratogenesis: general principles of clinical teratology.
  10. Lethal and Teratogenic Impacts of Imazapyr, Diquat Dibromide, and Glufosinate Ammonium Herbicide Formulations Using Frog Embryo Teratogenesis Assay-Xenopus (FETAX).